Tucatinib Plus Trastuzumab Demonstrates Durable Clinical Benefit in HER2-Positive Metastatic Colorectal Cancer
Clinical Summary:
-
Design/Population: This updated analysis of the phase 2 MOUNTAINEER trial evaluated long-term efficacy and safety of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer (mCRC).
-
Key Outcomes: Tucatinib plus trastuzumab demonstrated durable antitumor activity, with a confirmed objective response rate of 39.3%, median duration of response of 15.2 months, median progression-free survival of 8.1 months, and median overall survival of 23.9 months. The safety profile remained manageable with extended follow-up.
-
Clinical Relevance: These findings support dual HER2 blockade with tucatinib and trastuzumab as a durable, chemotherapy-free treatment option for HER2-positive, RAS wild-type mCRC and reinforce continued evaluation in earlier treatment settings.
Updated results from the phase 2 MOUNTAINEER trial demonstrated sustained clinical benefit and a manageable safety profile with tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer (mCRC).
"Phase 2 trials have demonstrated improved treatment responses to dual HER2-targeted combination therapies compared with standard later-line treatments in patients with treatment-refractory HER2-[positive] mCRC," stated John Strickler, MD, Duke University Medical Center, Durham, North Carolina, and coauthors. "One such dual combination regimen is tucatinib, an oral, highly selective HER2-targeted tyrosine kinase inhibitor, plus trastuzumab, an anti-HER2 monoclonal antibody."
In this multicenter, open-label trial, 84 patients with HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer received tucatinib plus trastuzumab after disease progression on fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This final analysis included a median follow-up of 32.4 months, representing an additional 16.1 months of follow-up beyond the primary analysis. Primary efficacy end points included confirmed objective response rate (ORR), duration of response, progression-free survival (PFS), and overall survival (OS).
At analysis, the confirmed ORR was 39.3%. Median duration of response was 15.2 months, median PFS was 8.1 months, and median OS was 23.9 months. Target lesion reduction was observed in 65% of evaluable patients.
Exploratory analyses demonstrated consistent treatment activity regardless of the HER2 testing platform used for patient identification. Clinical responses were also observed across a broad range of clinicopathologic subgroups, and investigators found no clear association between co-occurring genomic alterations and treatment efficacy. Longitudinal circulating tumor DNA analyses identified heterogeneous acquired resistance alterations at disease progression, although loss of HER2 amplification was uncommon.
The safety profile remained consistent with previous reports. The most common treatment-emergent adverse events were diarrhea (66.3%), fatigue (44.2%), and nausea (34.9%). Grade 3 treatment-emergent adverse events occurred in 33.7% of patients, most commonly hypertension (7%), diarrhea (3.5%), and abdominal pain (3.5%). Grade 4 treatment-emergent adverse events occurred in 7% of patients, few patients discontinued treatment because of adverse events, and no treatment-emergent deaths were reported.
“Tucatinib and trastuzumab showed durable and clinically meaningful efficacy that can be achieved with a dual HER2-targeted chemotherapy-free strategy," concluded Dr Strickler et al. “This analysis supports further investigation of tucatinib in combination with trastuzumab in earlier lines of therapy.”
Source:
Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): Final analysis. Nat Commun. Published online: January 12, 2026. doi: 10.1038/s41467-025-67824-z
